Compare WGO & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WGO | DRUG |
|---|---|---|
| Founded | 1958 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Pharmaceuticals and Biotechnology |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 771.7M | 778.4M |
| IPO Year | 1994 | 2020 |
| Metric | WGO | DRUG |
|---|---|---|
| Price | $26.46 | $60.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 6 |
| Target Price | $42.78 | ★ $129.25 |
| AVG Volume (30 Days) | ★ 474.3K | 71.9K |
| Earning Date | 03-25-2026 | 05-15-2026 |
| Dividend Yield | ★ 4.40% | N/A |
| EPS Growth | ★ 106.82 | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $1,985,674,000.00 | N/A |
| Revenue This Year | $5.10 | N/A |
| Revenue Next Year | $4.69 | N/A |
| P/E Ratio | $30.99 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.80 | $48.90 |
| 52 Week High | $50.16 | $123.75 |
| Indicator | WGO | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 31.27 | 33.69 |
| Support Level | N/A | $56.47 |
| Resistance Level | $31.33 | $78.35 |
| Average True Range (ATR) | 1.01 | 2.82 |
| MACD | -0.34 | -0.81 |
| Stochastic Oscillator | 6.94 | 24.63 |
Winnebago Industries manufactures Class A, B, and C motor homes along with towables, customized specialty vehicles, boats, and parts. Headquartered in Eden Prairie, Minnesota, Winnebago has been producing recreational vehicles since 1958. Revenue was $2.8 billion in fiscal 2025. Winnebago expanded into towables in 2010 with the acquisition of SunnyBrook and acquired Grand Design in 2016. Towables made up 84% of the firm's RV unit volume, up from 31% in fiscal 2016. The company's total fiscal 2025 RV unit volume was 36,911. Winnebago expanded into boating in 2018 with the purchase of Chris-Craft, bought premium motor home maker Newmar in 2019, and acquired Barletta pontoon boats in 2021. It also is developing electric and autonomous technology.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.